Summary by Moomoo AI
On December 28, 2023, Virpax Pharmaceuticals, Inc. held a special meeting where stockholders voted on three key proposals. The first proposal, which passed, was an amendment to the company's Certificate of Incorporation to effect a reverse stock split of the company's common stock at a ratio between 1-for-2 and 1-for-20, the exact ratio to be determined by the Board. The second and third proposals, however, were not approved by the stockholders. The second proposal was to amend the 2022 Equity Incentive Plan to increase the number of shares and the evergreen provision percentage. The third proposal was to adjourn the 2023 Special Meeting to a later date if necessary to solicit more votes if there were insufficient votes in favor of the first two proposals. The voting results were detailed in the Definitive Proxy Statement filed with the SEC on December 7, 2023.